Generic and specialty pharmaceuticals firm Mylan (Nasdaq: MYL) has announced lower than expected second quarter 2018 revenues of $2.81 billion, down 5% compared to the prior year period.
Following Generally Accepted Accounting Principles (GAAP), the earnings per share figure was $0.07, down 87% from 2017.
Analysts had forecast sales of around $2.96 billion, according to the Financial Times. Ahead of the opening bell in New York, shares in the firm were trading almost 5% lower than the previous close.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze